Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Newly diagnosed, Stage IIIb or IV NSCLC, chemo or other systemic therapy naive
One (1) unidimensionally measurable lesion
ECOG Performance Status of 0 or 1, no peripheral neuropathy \>Grade 1
Patients with clinically stable brain metastases on a stable dose of (or no longer requiring) dexamethasone at registration will be eligible. Patients who have received cranial radiation for brain metastases must be at least 4 weeks from last radiation treatment.
Recovery in full from any previous surgical procedure
No history of an acute cardiac or CNS event within 6 months of entry or current clinical evidence of congestive heart failure or non-stable coronary artery disease
You may not be if
Hypersensitivity to any of the 4 study drugs
Concurrent immunotherapy or participation in any investigational drug study within 4 weeks
Serious uncontrolled intercurrent medical or psychiatric illness and organ allograft
History of other malignancy within the last 5 years (except for squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix, or superficial transitional cell carcinoma of the bladder)
Patient is a pregnant or lactating female
Clareo Health | Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
